NeoTYPE GIST and Soft Tissue Tumor Profile

The NeoTYPE GIST/Soft Tissue Tumor Profile analyzes 35 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. •NGS (31 genes + 1 biomarker): AKT1, ATM, BRAF, CDKN2A, FGFR1, FGFR2, FGFR3, GNAS, HRAS, JAK3, KIT, KRAS, MAP2K1, MET, NF1, NRAS, NTRK1 fusions, NTRK2 fusions, NTRK3 fusions, PDGFRA, PIK3CA, PTEN, PTPN11, SDHA, SDHB, SDHC, SDHD, SMAD4, SMO, SRC, TP53, Tumor Mutation Burden (TMB) •FISH (2 FISH): MET, PTEN (tech-only available) •IHC (1 biomarker): PD-L1 22C3 (tech-only available)

LAB6032

GIST Profile, Soft Tissue Tumor Profile

FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixatives.

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <72 hours old preferred.

14 days

The GIST and Soft Tissue Tumor Profile characterizes primary or metastatic gastrointestinal stromal tumors, sarcomas, and other soft tissue primary or metastatic tumors of any histological subtype for the most significant genetic changes relevant to therapy decisions, prognosis, and clinical research. It is appropriate for patients with newly-diagnosed or recurrent disease, patients with an atypical clinical presentation, and patients with resistant disease to explore options in clinical trials.